HMGCR and breast cancer: Indeed, the oral administration of statins, which inhibit the rate-limiting enzyme in the mevalonate pathway HMG-CoA reductase, has been reported to improve the prognosis of breast cancer [19, 20], prostate cancer [21] and colorectal cancer [22].